Skip to main content
. 2012 Aug 2;7(8):e42043. doi: 10.1371/journal.pone.0042043

Figure 2. Progression-free survival (PFS) rates in stage I lung cancer patients who underwent computed tomography-guided needle biopsy (CTNB group) versus patients who did not (non-CTNB group).

Figure 2

(A) PFS was significantly reduced in the non-CTNB group in comparison to the CTNB group overall (CTNB group, n = 124; non-CTNB group, n = 197; p = 0.04, log-rank test). (B–D) When subgrouped according to tumor size into p-T1a (CTNB group, n = 79; non-CTNB group, n = 78; p = 0.55, log-rank test), pT1b (CTNB group, n = 25; non-CTNB group, n = 51; p = 0.44, log-rank test), or p-T2a (CTNB group, n = 20; non-CTNB group, n = 68; p = 0.36, log-rank test), the differences in PFS became insignificant.